Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients

BAŞPINAR, OSMAN; GÜÇLÜ, KENAN; baskol, gulden; bayram, fahri; AYDOGDU, AYDOGAN

doi:10.56615/tkbd.2022.07

Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients

Kenan GUCLU, (Ahi Evran Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Kırşehir, Türkiye)

Fahri BAYRAM, (Erciyes Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Anabilim Dalı, Kayseri, Türkiye)

Gülden BAŞKOL, (Erciyes Üniversitesi Tıp Fakültesi, Biyokimya Anabilim Dalı, Kayseri, Türkiye)

Osman BAŞPINAR, (Kayseri Eğitim ve Araştırma Hastanesi, Dahiliye Kliniği, Kayseri, Türkiye)

Aydoğan AYDOĞDU (Gülhane Eğitim ve Araştırma Hastanesi, Endokrinoloji ve Metabolizma Kliniği, Ankara, Türkiye)

Türk Klinik Biyokimya Dergisi

4 0

Yıl: 2022 Cilt: 20 Sayı: 1 Sayfa Aralığı: 54 - 62 Metin Dili: İngilizce DOI: 10.56615/tkbd.2022.07 İndeks Tarihi: 28-02-2023

Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients

Öz:

Aim: To investigate the presence of oxidative stress and dyslipidemia , which increase cardiovascular risk, and the effect of gonadotropin replacement therapy on these parameters in patients with Idiopathic Hypogonadotropic Hypogonadism (IHH). Material and Methods: This was a phase IV, non-randomized, case-controlled study. Male patients diagnosed with IHH (n=30), and a control group of healthy participants with similar age and body mass index (BMI) (n=20) were included. Oxidative stress markers, lipids and apolipoprotein levels were measured before and after gonadotropin treatment and compared with healthy controls. Results: After treatment, a dramatic decrease was obse rved in high-density lipoprotein (HDL), low- density lipoprotein (LDL), advanced oxidation pr otein products (AOPP), malondialdehyde (MDA) and nitric oxide (NO) levels, while a significant increase in thiol level was detected (p<0.05). Conclusion: The data obtained indicated the presence of dyslipidemia and an increase in oxidative stress in hypogonadism cases, and showed that gonadotropin treatment reduced the oxidative stress of patients and positively affected their lipid profile.

Anahtar Kelime:

Hipogonad Hastalarda Lipid Profili ve Oksidatif Stres Markerlarının Tedavi ile Değişimi

Öz:

Amaç: İdiyopatik Hipogonadotropik Hipogonadizm (İHH) hastalarında kardiyovasküler riski artıran oksidatif stres ve dislipidemi varlığını ve gonadotropin replasman tedavisinin bu parametreler üzerindeki etkisini araştırmak. Materyal ve Metod: Çalışmamız faz IV, randomize olmayan, vaka kontrollü bir çalışmaydı. Çalışmaya, İHH tanılı erkek hastalar (n=30) ile benzer yaş ve vücut kitle indeksine (VKİ) sahip sağlıklı kontrol grubu (n=20) dahil edildi. Oksidatif stres belirteçleri, lipidler ve apolipoprotein seviyeleri, gonadotropin tedavisinden önce ve sonra ölçüldü ve sağlıklı kontrollerle karşılaştırıldı. Bulgular: Tedavi sonrası yüksek dansiteli lipoprotein (HDL), düşük dansiteli lipoprotein (LDL), ileri oksidasyon protein ürünleri (AOPP), malondialdehit (MDA) ve nitrik oksit (NO) seviyelerinde dramatik bir düşüş görülürken tiyol seviyesinde önemli bir artış tespit edildi (p<0.05). Sonuç: Elde edilen veriler hipogonadizm olgularında dislipidemi varlığına ve oksidatif stres artışına işaret etmiştir ve gonadotropin tedavisinin bu hastaların oksidatif stresini azalttığını ve lipid profilini olumlu yönde etkilediğini göstermiştir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Alkadi H. A Review on Free Radicals and Antioxidants. Infect Disord Drug Targets. 2020;20(1):16-26
2. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160 (1):1-40.
3. Mannucci A, Argento FR, Fini E, Coccia ME, Taddei N, Becatti M, et al. The Impact of Oxidative Stress in Male Infertility. Front Mol Biosci. 2022; 8:799294.
4. Leisegang K, Roychoudhury S, Slama P, Finelli R. The Mechanisms and Management of Age-Related Oxidative Stress in Male Hypogonadism Associated with Non-communicable Chronic Disease. Antioxidants. 2021;18(11):1834.
5. Unluhizarci K, Sık SK, Keti DB, Kose K, Hacıoglu A, Karaca Z. Treatment of male hypogonadism partially reverses oxidative stress in patients with hypogonadism. Endocr J. 2020;67(9):935-940
6. Mancini A, Leone E, Festa R, Grande G, Silvestrini A, de Marinis L, et al. Effects of testosterone on antioxidant systems in male secondary hypogonadism. J Androl. 2008;29(6):622-9.
7. Cicek OSY, Kaya G, Alyuruk B, Doger E, Girisen T, Filiz S. The association of seminal oxidation reduction potential with sperm parameters in patients with unexplained and male factor ınfertility. Int Braz J Urol. 2021;47(1):112-119.
8. Matsumoto AM, Bremner WJ. Testicular disorders. In: Melmed S, Polansky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook of Endocrinology. 13th ed. New York, NY: Elsevier; 2016:688–777.
9. Aitken RJ, Baker MA. Oxidative stress, sperm survival and fertility control. Mol Cell Endocrinol. 2006;250 (1-2):66-9.
10. Rastrelli G, Filippi S, Sforza A, Maggi M, Corona G. Metabolic Syndrome in Male Hypogonadism. Front Horm Res. 2018; 49:131-155.
11. Kloner RA. Testosterone and Cardiovascular Health: Safety of Treatment of Hypogonadism. Sex Med Rev. 2015;3(1):56-62.
12. Doulamis IP, Tzani A, Konstantopoulos P, Daskalopoulou A, Spinos T, Bletsa E, et al. Experimental hypogonadism: insulin resistance, biochemical changes and effect of testosterone substitution. J Basic Clin Physiol Pharmacol. 2019;4;30(3).
13. Anawalt BD, Yeap BB. Conclusions about testosterone therapy and cardiovascular risk. Asian J Androl. 2018;20(2):152-153.
14. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol . 1998;161(5):2524-32.
15. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med. 1993;121 (2):257- 62.
16. Kim SH, Park JJ, Kim KH, Yang HJ, Kim DS, Lee CH, et al. Efficacy of testosterone replacement therapy for treating metabolic disturbances in late-onset hypogonadism: a systematic review and metaanalysis. Int Urol Nephrol. 2021;53(9):1733-1746.
17. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154 (6):899-906.
18. Cai X, Tian Y, Wu T, Cao CX, Li H, Wang KJ. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian J Androl. 2014;16 (1):146-52.
19. Bhasin S, Woodhouse L, Storer TW. Proof of the effect of testosterone on skeletal muscle. J Endocrinol. 2001;170 (1):27-38.
20. Naharci MI, Pinar M, Bolu E, Olgun A. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract. 2007;13 (6):629-35.
21. Haymana C, Sonmez A, Aydogdu A, Tapan S, Basaran Y, Meric C, et al. Visceral adiposity index and triglyceride/high-density lipoprotein cholesterol ratio in hypogonadism. Arch Endocrinol Metab. 2017;61(3):282-287.
22. Tan KC, Shiu SW, Pang RW, Kung AW. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrinol (Oxf). 1998;48 (2):187-94.
23. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89 (7):3313-8.
24. Bolu E, Sonmez A, Tapan S, Taslipinar A, Aydogdu A, Meric C, et al. HDL cholesterol subfractions and the effect of testosterone replacement in hypogonadism. Horm Metab Res. 2013;45 (6):443- 8.
25. Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, et al. Apolipoprotein (a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160-7.
26. Kargin R, Emiroglu Y, Pala S, Akcakoyun M, Aung SM, Candan Ö, et al. Association Between Apolipoprotein-B100 and Apolipoprotein-A1 in Patients with Coronary Slow Flow. Kosuyolu Kalp Derg. 2010;13 (2):11-15.
27. Comini MA. Measurement and meaning of cellular thiol:disufhide redox status. Free Radic Res. 2016;50(2):246-71.
28. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int. 2000;58 (6):2571- 8.
29. Ulrich K, Jakob U. The role of thiols in antioxidant systems. Free Radic Biol Med. 2019;20;140:14-27.
30. Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges. Anal Biochem. 2017;1;524:13-30.
31. C. Haymana, A. Aydoğdu, B. Soykut, O. Erdem, T. Ibrahimov, M. Dinc, et al. Oxidative stress status in congenital hypogonadism. Toxicology Mechanisms and Methods, 2017; 27(6), 451-7.
32. Lee NP, Cheng CY. Nitric oxide/nitric oxide synthase, spermatogenesis, and tight junction dynamics. Biology of reproduction. 2004;70 (2):267-76.
33. Tenopoulou M, Doulias PT. Endothelial nitric oxide synthase-derived nitric oxide in the regulation of metabolism. F1000Res. 2020;9: F1000 Faculty Rev1190.
34. Totzeck M, Hendgen-Cotta UB, Rassaf T. NitriteNitric Oxide Signaling and Cardioprotection. Adv Exp Med Biol. 2017; 982:335-46.
35. Preedy MEJ, Baliga RS, Hobbs AJ. Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure. J Cardiovasc Pharmacol. 2020;75(5):370-384.
36. Gholinezhad M, Aliarab A, Abbaszadeh-Goudarzi G, Yousefnia-Pasha Y, Samadaian N, Rasolpour-Roshan K, et al. Nitric oxide, 8-hydroxydeoxyguanosine, and total antioxidant capacity in human seminal plasma of infertile men and their relationship with sperm parameters. Clin Exp Reprod Med. 2020;47(1):54- 60.
37. Yasuda M, Ide H, Furuya K, Yoshii T, Nishio K, Saito K, et al. Salivary 8-OHdG: a useful biomarker for predicting severe ED and hypogonadism. J Sex Med. 2008;5 (6):1482-91.

APA	GÜÇLÜ K, bayram f, baskol g, BAŞPINAR O, AYDOGDU A (2022). Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients. , 54 - 62. 10.56615/tkbd.2022.07
Chicago	GÜÇLÜ KENAN,bayram fahri,baskol gulden,BAŞPINAR OSMAN,AYDOGDU AYDOGAN Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients. (2022): 54 - 62. 10.56615/tkbd.2022.07
MLA	GÜÇLÜ KENAN,bayram fahri,baskol gulden,BAŞPINAR OSMAN,AYDOGDU AYDOGAN Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients. , 2022, ss.54 - 62. 10.56615/tkbd.2022.07
AMA	GÜÇLÜ K,bayram f,baskol g,BAŞPINAR O,AYDOGDU A Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients. . 2022; 54 - 62. 10.56615/tkbd.2022.07
Vancouver	GÜÇLÜ K,bayram f,baskol g,BAŞPINAR O,AYDOGDU A Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients. . 2022; 54 - 62. 10.56615/tkbd.2022.07
IEEE	GÜÇLÜ K,bayram f,baskol g,BAŞPINAR O,AYDOGDU A "Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients." , ss.54 - 62, 2022. 10.56615/tkbd.2022.07
ISNAD	GÜÇLÜ, KENAN vd. "Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients". (2022), 54-62. https://doi.org/10.56615/tkbd.2022.07

APA	GÜÇLÜ K, bayram f, baskol g, BAŞPINAR O, AYDOGDU A (2022). Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients. Türk Klinik Biyokimya Dergisi, 20(1), 54 - 62. 10.56615/tkbd.2022.07
Chicago	GÜÇLÜ KENAN,bayram fahri,baskol gulden,BAŞPINAR OSMAN,AYDOGDU AYDOGAN Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients. Türk Klinik Biyokimya Dergisi 20, no.1 (2022): 54 - 62. 10.56615/tkbd.2022.07
MLA	GÜÇLÜ KENAN,bayram fahri,baskol gulden,BAŞPINAR OSMAN,AYDOGDU AYDOGAN Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients. Türk Klinik Biyokimya Dergisi, vol.20, no.1, 2022, ss.54 - 62. 10.56615/tkbd.2022.07
AMA	GÜÇLÜ K,bayram f,baskol g,BAŞPINAR O,AYDOGDU A Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients. Türk Klinik Biyokimya Dergisi. 2022; 20(1): 54 - 62. 10.56615/tkbd.2022.07
Vancouver	GÜÇLÜ K,bayram f,baskol g,BAŞPINAR O,AYDOGDU A Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients. Türk Klinik Biyokimya Dergisi. 2022; 20(1): 54 - 62. 10.56615/tkbd.2022.07
IEEE	GÜÇLÜ K,bayram f,baskol g,BAŞPINAR O,AYDOGDU A "Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients." Türk Klinik Biyokimya Dergisi, 20, ss.54 - 62, 2022. 10.56615/tkbd.2022.07
ISNAD	GÜÇLÜ, KENAN vd. "Change of Lipid Profile and Oxidative Stress Markers with Treatment in Hypogonad Patients". Türk Klinik Biyokimya Dergisi 20/1 (2022), 54-62. https://doi.org/10.56615/tkbd.2022.07